Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic bone marrow-derived MSC therapy safety in kidney transplant recipients
NL-OMON40295Active, not recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Mar 2015
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Open-label, single-arm trial of allogeneic bone marrow-derived mesenchymal stromal cells in kidney allograft rejection and Transplant Nephropathy, sponsored by Leiden University Medical Center. Primary endpoint: Composite safety endpoint of biopsy-proven acute rejection or graft loss. Started Mar 2015; status: active, not recruiting.
02
Drugs
allogeneic bone marrow-derived mesenchymal stromal cells
03
Conditions
kidney allograft rejectionTransplant Nephropathy
Beyond the preview
Go deeper on NL-OMON40295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40295.